GC
RMD icon

Grimes & Company’s ResMed RMD Stock Holding History

Grimes & Company’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,575
Closed -$202K – 205
2015
Q2 		$202K Sell
3,575
-3,794
-51% -$239K 0.03% 176
2015
Q1 		$529K Sell
7,369
-69,911
-90% -$4.54M 0.13% 93
2014
Q4 		$4.33M Buy
77,280
+804
+1% +$42K 1.12% 35
2014
Q3 		$3.77M Sell
76,476
-119
-0.2% -$6.06K 0.99% 45
2014
Q2 		$3.88M Sell
76,595
-401
-0.5% -$19.9K 1.02% 43
2014
Q1 		$3.44M Buy
76,996
+8,123
+12% +$365K 0.97% 47
2013
Q4 		$3.24M Buy
68,873
+4,836
+8% +$245K 0.97% 48
2013
Q3 		$3.38M Sell
64,037
-5,688
-8% -$276K 1.14% 39
2013
Q2 		$3.15M Buy
+69,725
New +$3.31M 1.15% 41

Other funds holding RMD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Grimes & Company's RMD Position: Q3 2015 in Review

Grimes & Company sold out of ResMed (RMD) in Q3 2015, closing a stake of 3,575 shares — an estimated $202K sold.

Grimes & Company first reported a position in RMD in Q2 2013 and held it in 9 quarters. The position peaked at $4.33M in Q4 2014. 313 funds tracked by Wall St. Rank hold RMD as of Q3 2015.

  • Grimes & Company reported no remaining ResMed position as of Q3 2015 after selling out during the quarter.
  • Grimes & Company sold 3,575 ResMed shares in Q3 2015, an estimated $202K.
  • Grimes & Company first reported a position in ResMed in Q2 2013 and held it in 9 quarters.
  • Grimes & Company's ResMed position peaked at $4.33M in Q4 2014.
  • 313 funds tracked by Wall St. Rank held ResMed as of Q3 2015.

Based on Grimes & Company's 13F filing for Q3 2015, filed 8 Oct 2015.